Treatment Options
Choosing a Weight Management Injection in Singapore
Three molecules are licensed for medical weight management in Singapore. How the choice is actually made clinically, and why no website can rank them for you.
Three molecules are licensed for medical weight management in Singapore. People naturally want to know which one to choose, and a certain kind of website will happily rank them. This page will not, and it is worth explaining why the ranking you are looking for does not exist in any honest form.
What is actually licensed here
Weight management is a registered indication for three substances in Singapore: semaglutide (weekly), tirzepatide (weekly, acting on two hormone receptors), and liraglutide (daily). Each has its own product information, its own dose schedule, and BMI thresholds that are broadly similar — generally 30 or above, or 27 to below 30 with at least one weight-related condition such as prediabetes, type 2 diabetes, high blood pressure, abnormal cholesterol, obstructive sleep apnoea or cardiovascular disease.
Notice what is not in that list. Two very well-known brand names that people search for constantly are registered in Singapore for type 2 diabetes, not for weight management. They are discussed elsewhere on this site for exactly that reason.
Why no ranking exists
Clinical trials differ in ways that make league tables dishonest:
- Different populations. Entry criteria, baseline BMI and the proportion of participants with diabetes vary between programmes.
- Different designs and comparators. A trial against placebo and a trial against another active medicine answer different questions.
- Different endpoints and timepoints. Percentage weight change at 68 weeks is not the same measure as proportion achieving a categorical loss at 52 weeks.
- Head-to-head data is limited. Where it exists, it is rarely long enough to speak to maintenance, which is the outcome that matters most to patients.
So when a page presents a neat ordering, it is usually comparing numbers that were never meant to be compared. The same caution applies to any percentage quoted without its trial population.
What actually drives the decision
In a real consultation, the choice turns on things a website cannot see.
Your BMI and comorbidities. The licensed thresholds are the entry ticket, and specific conditions change what is appropriate — kidney function, liver disease, gallbladder history and pancreatitis history all matter.
Your other medications. Interactions and cumulative effects are reviewed, particularly with diabetes medicines, because appetite suppression plus glucose-lowering treatment can push blood sugar too low.
Contraindications. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 is a contraindication for this class. Pregnancy, plans to conceive, or breastfeeding rules treatment out.
Daily or weekly. This is underrated. A weekly injection is fewer needles; a daily injection is easier to stop or adjust quickly and builds a routine. Both are legitimate reasons, and only you know which fits your life.
Tolerability. Gastrointestinal side effects are the main reason people stop. Individual response varies, and titration speed is adjusted accordingly — which is why “which one is gentler” has no universal answer.
Monitoring and review structure. One of these medicines carries an explicit checkpoint in its label: discontinue after 12 weeks at the maintenance dose if 5% of body weight has not been lost. For others, review points are set clinically. A programme that actually schedules those reviews is worth more than the molecule.
What happens at the end. Appetite returns when treatment stops. The exit plan matters more than the starting choice, and it is the part most programmes leave vague.
What should not drive the decision
- What is trending on social media. Popularity is not an indication.
- What worked for a friend. Response varies, and their contraindications are not yours.
- A headline price per pen without knowing the dose it corresponds to and whether the price changes as the dose rises.
- A single number from a trial presented without its population or timepoint.
The uncomfortable part
For most people, the medicine is not the largest variable — the programme is. Assessment, baseline tests, titration, scheduled review, side-effect management, protein and resistance activity to protect muscle, and a maintenance plan are what separate a treatment that holds from a course of injections that ends in regain.
That is also why identical medicines produce very different outcomes in different clinics.
Questions worth asking any clinic
- Is weight management a registered indication for what you are proposing, in Singapore?
- What are the baseline tests, and what do they involve?
- What is the titration schedule, and who do I contact between reviews?
- When are my review points, and what happens if the response is inadequate?
- What is the plan for stopping, and what comes after?
- What does the whole course involve at each dose, in writing?
Where this fits at Accord Medical
The medical weight loss programme begins with assessment rather than a product. If you want the specifics of each licensed substance, these explain what the Singapore label covers: tirzepatide, semaglutide for weight management and liraglutide. The GLP-1 guide covers the class as a whole.
Details of what an assessment involves are on the consultation rates page linked in the main navigation. The starting point is a conversation, in clinic or by teleconsult.
To arrange one, book a consultation.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for medical concerns, diagnosis, or treatment. Accord Medical Clinic is an MOH-registered medical clinic in Singapore. Dr Joseph Wang (Family Physician) provides medical weight management consultations.
Licensing information referenced from the Singapore National Drug Formulary product information for semaglutide, tirzepatide and liraglutide products registered for weight management, last reviewed October 2026.
Frequently asked questions
Which weight management injection is the right one?
There is no single answer, and any page that gives you one without assessing you is guessing. The choice depends on your BMI and whether you meet the licensed thresholds, other medical conditions, what medications you already take, how you tolerate side effects, whether a daily or weekly schedule suits you, and what monitoring you need.
Can you tell me which one produces the most weight loss?
No — not honestly. The trials behind these medicines used different populations, different designs and different comparators, so placing them side by side as a ranking would be misleading. What can be said is that all three are licensed for weight management in Singapore, and that response varies between individuals.
Do I have to stay on it forever?
There is no rule requiring lifetime treatment, but appetite returns when treatment stops. The maintenance plan — food, activity, muscle preservation and follow-up — is what determines whether the weight stays off, so it is designed at the start rather than improvised.
Is the newest one always the right choice?
No. Newer medicines have shorter real-world track records. Being well established is a genuine advantage for some patients, and a doctor may reasonably prefer a medicine with a longer safety history depending on your circumstances.
What if none of them suit me?
Then the honest answer is that medical treatment is not indicated right now, and a structured non-pharmacological plan is the more appropriate route. That is a real outcome of an assessment, not a failure to sell you something.
How quickly would I know whether it is working?
Reviews are scheduled at intervals, and the useful signal is a trend over months rather than any single week's reading. One of these medicines carries an explicit three-month checkpoint in its product information; for the others, your doctor sets the review points.
